CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Share Repurchase Programs Total Shareholders' Equity Attributable to Bruker Corporation	Share Repurchase Programs Common Stock	Share Repurchase Programs Treasury Stock	Share Repurchase Programs	Other Treasury Stock Acquired Total Shareholders' Equity Attributable to Bruker Corporation	Other Treasury Stock Acquired Common Stock	Other Treasury Stock Acquired Treasury Stock	Other Treasury Stock Acquired	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interest	Total
Balance at beginning of period at Dec. 31, 2016									$ 686.4	$ 1.7	$ (249.3)	$ 124.7	$ 885.2	$ (75.9)	$ 6.7		$ 693.1
Balance (in shares) at Dec. 31, 2016										159,854,695	10,698,195
Increase (Decrease) in Stockholders' Equity
Restricted shares terminated (in shares)										(4,053)	4,053
Stock options exercised									20.4			20.4					20.4
Stock options exercised (in shares)										1,263,767
Restricted stock units vested									(0.3)			(0.3)					(0.3)
Restricted stock units vested (in shares)										58,419
Stock based compensation									11.0			11.0					11.0
Excess tax benefit related to exercise of stock awards									3.6				3.6				3.6
Shares repurchased	$ (152.2)		$ (152.2)	$ (152.2)
Shares repurchased (in shares)		(5,318,063)	5,318,063
Shares issued for acquisition									0.6		$ 0.5	0.1					0.6
Shares issued for acquisition (in shares)										18,110	(18,110)
Treasury stock acquired					$ (0.2)		$ (0.2)	$ (0.2)
Treasury stock acquired (in shares)						(6,898)	6,898
Distributions to noncontrolling interests															(1.0)		(1.0)
Cash dividends paid to common stockholders									(25.4)				(25.4)				(25.4)
Consolidated net income									78.6				78.6		1.7		80.3
Other comprehensive income (loss)									102.9					102.9	0.7		103.6
Balance at end of period at Dec. 31, 2017									725.4	$ 1.7	$ (401.2)	155.9	942.0	27.0	8.1		733.5
Balance (in shares) at Dec. 31, 2017										155,865,977	16,009,099
Increase (Decrease) in Stockholders' Equity
Restricted shares issued (in shares)											6,553
Restricted shares terminated (in shares)										(6,553)
Stock options exercised									10.3			10.3					10.3
Stock options exercised (in shares)										575,372
Restricted stock units vested									(0.6)			(0.6)					(0.6)
Restricted stock units vested (in shares)										183,772
Stock based compensation									11.3			11.3					11.3
Shares returned for acquisition									(0.1)		$ (0.1)						(0.1)
Shares returned for acquisition (in shares)										(2,123)	2,123
Treasury stock acquired					(0.2)		$ (0.2)	(0.2)
Treasury stock acquired (in shares)						(7,105)	7,105
Acquired 80% interest in Hain LifeScience GmbH																$ 23.2
Distributions to noncontrolling interests															(0.9)		(0.9)
Adoption impact from new revenue standard ASC 606 | ASC 606									5.9				5.9		0.2		6.1
Cash dividends paid to common stockholders									(25.1)				(25.1)				(25.1)
Consolidated net income									179.7				179.7		1.3	(0.2)	181.0
Other comprehensive income (loss)									(10.0)					(10.0)	(0.2)	(0.4)	(10.2)
Balance at end of period at Dec. 31, 2018									896.6	$ 1.7	$ (401.5)	176.9	1,102.5	17.0	8.5	22.6	905.1
Balance (in shares) at Dec. 31, 2018										156,609,340	16,024,880
Increase (Decrease) in Stockholders' Equity
Stock options exercised									12.0			12.0					12.0
Stock options exercised (in shares)										626,796
Restricted stock units vested									(1.1)			(1.1)					(1.1)
Restricted stock units vested (in shares)										241,359
Stock based compensation									11.9			11.9					11.9
Shares repurchased									(142.3)		$ (142.3)						(142.3)
Shares repurchased (in shares)										(3,323,104)	3,323,104
Shares issued for acquisition (in shares)										3,087	(3,087)
Shares returned for acquisition									0.1		$ 0.1						0.1
Treasury stock acquired					$ (0.1)		$ (0.1)	$ (0.1)
Treasury stock acquired (in shares)						(1,680)	1,680
Cash dividends paid to common stockholders									(25.0)				(25.0)				(25.0)
Consolidated net income									197.2				197.2		1.9	(1.1)	199.1
Other comprehensive income (loss)									(42.5)					(42.5)	(0.1)	(0.4)	(42.6)
Balance at end of period at Dec. 31, 2019									$ 906.8	$ 1.7	$ (543.8)	$ 199.7	$ 1,274.7	$ (25.5)	$ 10.3	$ 21.1	$ 917.1
Balance (in shares) at Dec. 31, 2019										154,155,798	19,346,577